ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Multiple Doses and Regimens of XL184 (Cabozantinib) in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01068782
Recruitment Status : Completed
First Posted : February 15, 2010
Last Update Posted : July 30, 2014
Sponsor:
Information provided by (Responsible Party):
Exelixis

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : May 2011
  Actual Study Completion Date : October 2013